nct_id: NCT02934568
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2016-10-17'
study_start_date: '2016-12-15'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: LEE011'
long_title: An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated
  in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit
  From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
last_updated: '2024-04-26'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Novartis
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 50
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 1. Patient is currently enrolled in an eligible Novartis-sponsored study and receiving
  ribociclib (LEE011) as single agent or in combination with other investigational
  treatment.
- 2. Patient is currently deriving clinical benefit from the study treatment, as determined
  by the investigator.
- 'Exclude - Exclusion Criteria:'
- Exclude - 1. Patient has been permanently discontinued from ribociclib (LEE011)
  in the parent protocol for any reason.
- Exclude - 2. Patients who do not meet parent protocol criteria to continue study
  treatment.
short_title: Ribociclib (LEE011) Rollover Study for Continued Access
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Novartis Pharmaceuticals
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This study is to allow continued use of ribociclib (LEE011) as single agent
  or in combination with other investigational treatments in patients benefitting
  from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that
  has reached its primary objective(s) or has been halted for other reasons.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: LEE011
      arm_internal_id: 0
      arm_description: All patients in all combinations with LEE011 will be entered
        in one arm.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: LEE011'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        oncotree_primary_diagnosis: _SOLID_
